Katarina Ageborg, EVP of sustainability at AstraZeneca

Katarina Ageborg was appointed head of sustainability at AstraZeneca in 2015 and has served as chief compliance officer since 2011. 
AstraZeneca recently released its 7th annual sustainability report, focused heavily on issues such as access to healthcare, environmental protection, and ethics and transparency strategy. 
This article is part of a series analyzing ESG reporting trends. For more click here.

The year 2021 was one of big impact for pharmaceutical leader AstraZeneca, which supplied over 2.5 billion doses of COVID-19 vaccines to more than 180 countries. But when it comes to ESG reporting, the British-Swedish pharmaceutical and biotechnology leader based in Cambridge, England, has also made sure to focus squarely on the areas where they make the most impact, that are measurable, and that have a governance process. 

“We have been sticking to focusing on issues such as access to healthcare, environmental protection, and our ethics and transparency strategy, ” Katarina Ageborg, who was appointed EVP of sustainability in 2015, told Insider. “It’s about equitable access, affordability and pricing, as well as healthcare resilience, and then an ambitious zero carbon goal, product sustainability, and natural resources.” Since the company’s culture is also very driven around its corporate values, the focus on ethics and transparency is also crucial, she added: “As I have also served as chief compliance officer since 2011, that piece is close to my heart.” 

The company has published an annual report on ESG issues since she took on the EVP of sustainability role, and sustainability “is part of our organizational DNA, embedded from the lab to the patient, and delivered thanks to the efforts of over 80,000 employees,” Ageborg wrote in the opening to AstraZeneca’s 2021 report. 

But she joked that the company has also tried to rein in its size. “This year’s report is a very big document, but we made it shorter than last year, believe it or not,” she said. 

Short or long, Ageborg emphasized that ESG reporting needs to be accurate and transparent. “We also want to have as much data as possible without overloading people, so that those from the outside can evaluate what we are doing objectively while still keeping it interesting,” she said. “We make sure that we have the most up-to-date, accurate information even for a big organization with lots of groups feeding into the report — it’s about fine-tuning it, making it better and clearer, and listening to …read more

Source:: Business Insider


AstraZeneca’s EVP of sustainability says the focus on ethics and transparency in its ESG report is crucial in reflecting the company’s values

Leave a Reply

Your email address will not be published. Required fields are marked *